Project Grant R01CA287734
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$670K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award of $678,723 from the National Cancer Institute (NCI) under CFDA 93.395, the Cancer Treatment Research program, supports research on the regulation and clinical significance of programmed death ligand 1 (PD-L1) in lung cancer. The principal aims are to evaluate the clinical utility of PD-L1 and an associated E3 ligase enzyme in lung cancer diagnosis and prognosis (Aim 1), and to investigate the molecular mechanisms by which PD-L1 ubiquitination and trafficking impact...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
The National Cancer Institute (NCI) awarded a $162,080 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Johns Hopkins University. The grant supports a study to visualize B cell infiltration and aggregation within the tumor microenvironment. Specifically, the study uses transgenic mouse models and intravital microscopy to investigate how high endothelial venules facilitate B cell entry into tumors and the formation of tertiary lymphoid structures,...
This Project Grant award of $421,685 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center aims to investigate how the LIFR-LCN2 pathway in liver cancer suppresses the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The research project has two specific aims: 1) to investigate whether the LIFR-LCN2 pathway inhibits the effector function of CD8+ T cells, and 2) to determine...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $424,836 to The University of Texas MD Anderson Cancer Center to conduct research on detecting and eliminating drug-tolerant persister cells in small cell lung cancer (SCLC). The research aims to: Molecularly characterize drug-tolerant persister cells in SCLC models treated with standard chemotherapy to track their emergence and trajectory. Evaluate the ability of a recently...
This Project Grant award of $577,818 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new effective therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers treated with radiotherapy. The funded research project will: 1) Dissect the mechanisms by which the immune checkpoint molecule B7-H3 impairs CD8 T cell cytotoxicity, using proximity labeling technologies and mouse models, and...
This federal Project Grant award, totaling $244,228.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will fund a research project led by the University of Texas MD Anderson Cancer Center to develop a functional proteomics approach for accurately mapping patient tumor samples to preclinical lung cancer models. The key objectives are to: 1) expand proteomic profiling of lung cancer patient-derived xenograft...
This Project Grant award from the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct research on "Deciphering the Structural Determinants of Response and Resistance to HER2-Targeted Antibody-Drug Conjugates and Tyrosine Kinase Inhibitors for HER2-Mutant Non-Small Cell Lung Cancer". The 5-year project aims to comprehensively characterize the landscape of HER2 mutations...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...